Drugs / 177Lu-PSMA-EB-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05613738 | Nov 2022 → Jun 2025 overdue | castration-resistant prostate carcinoma | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-PSMA-EB-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05613738 ↗ |
| Known as | [177Lu]Lu-LNC1003 | “PURPOSE: This translational study aimed to determine the maximum tolerated dose (MTD), safety, dosimetry, and therapeutic efficacy of 177Lu-PSMA-EB-01 (denoted as...” PMID 37864592 ↗ Oct 2023 |
| Modality | Other / unclassified | “177Lu-PSMA-EB-01, a new PSMA-specific radiopharmaceutical” NCT05613738 ↗ |
| Route | Intravenous | “All patients were intravenous injected with single dose 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01” NCT05613738 ↗ |